(2012) Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus. Chinese Journal of Integrative Medicine /Park JW, Yoon J, Cho CK, Lee YW, Yoo HS. Survival anal- ysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus [published online ...
Objective:To evaluate the efficacy of HangAm-Plus(HAP) on stage IV metastatic gastric cancer by analyzing the treated patients' overall survival outcome.Methods:Following the study eligibility, overall survival and one year survival rate of 44 stage IV metastatic gastric cancer patients who visited ...
signifying that lncRNA H19 is a unitary prognostic biomarker of tumor recurrence [123]. The presence of lncRNA SNHG16, TTN-AS1 and PCGEM1 in the tissues of cancer patients accentuates the malignant features of GIC cells, culminating in a diminished survival rate with an unfavorable...
The prognosis of metastatic gastric cancer (GC) remains dismal, with a median survival of 10 months. Historically, primary tumor resection was not
(CRC) is the most prevalent GIC which accounts for 44% of all cancer cases, followed by pancreatic cancer (PC) which has a 5-year survival rate of less than 11% and is the most lethal cancer [1]. Furthermore, global GIC morbidity and mortality continue to rise [1]. Metastatic ...
- 《Gastric Cancer》 被引量: 72发表: 2011年 Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy KH Kim,KW Lee,SK Baek.Survival benefit of gastrectomy +/? metastasectomy in patients with metastatic gastric cancer receiving chemotherapy[]....
Purpose The impact of post-progression survival (PPS) on the overall survival (OS) of patients with advanced gastric cancer (AGC) has not yet been reported... Kohei,Shitara,Keitaro,... - 《Journal of Cancer Research & Clinical Oncology》 被引量: 13发表: 2013年 Mitomycin C and capecitabine...
2a). Median survival was 45 d post-electroporation (Fig. 2a). In contrast, mice electroporated with either MYC or Cas9-sgp53 vector alone did not develop tumors within 1 year (Fig. 2a). Fig. 2: CIN and GS gastric cancer EPO-GEMMs recapitulate hallmark histological and molecular ...
Findings In this subgroup analysis of a randomized clinical trial, trifluridine/tipiracil treatment improved overall survival and progression-free survival compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer and who had or had not undergone gastrec...
Gastric CancerKim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, et al. Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer. 2011;14:130-8.KH Kim,KW Lee,SK Baek.Survival benefit of gastrectomy +/?